Review



cd69  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bioss cd69
    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and <t>CD69.</t> Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd69/product/Bioss
    Average 94 stars, based on 12 article reviews
    cd69 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus"

    Article Title: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus

    Journal: British Journal of Cancer

    doi: 10.1038/s41416-024-02583-0

    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Figure Legend Snippet: a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.

    Techniques Used: Staining, Immunohistochemical staining



    Similar Products

    93
    Bio-Techne corporation human cd69 antibody
    Human Cd69 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd69 antibody/product/Bio-Techne corporation
    Average 93 stars, based on 1 article reviews
    human cd69 antibody - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    cd69  (Bioss)
    94
    Bioss cd69
    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and <t>CD69.</t> Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd69/product/Bioss
    Average 94 stars, based on 1 article reviews
    cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Proteintech rabbit polyclonal anti cd69
    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and <t>CD69.</t> Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Rabbit Polyclonal Anti Cd69, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti cd69/product/Proteintech
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal anti cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    91
    Atlas Antibodies hpa050525 atlas antibodies cd103 polyclonal
    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and <t>CD69.</t> Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Hpa050525 Atlas Antibodies Cd103 Polyclonal, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpa050525 atlas antibodies cd103 polyclonal/product/Atlas Antibodies
    Average 91 stars, based on 1 article reviews
    hpa050525 atlas antibodies cd103 polyclonal - by Bioz Stars, 2026-02
    91/100 stars
      Buy from Supplier

    86
    Danaher Inc anti cd69 rabbit polyclonal antibody
    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and <t>CD69.</t> Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.
    Anti Cd69 Rabbit Polyclonal Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd69 rabbit polyclonal antibody/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    anti cd69 rabbit polyclonal antibody - by Bioz Stars, 2026-02
    86/100 stars
      Buy from Supplier

    93
    Proteintech rabbit anti cd69 polyclonal antibody
    SCFAs alleviate inflammatory cell activities in gut ILC2 cells. (a) t-SNE feature plots revealing profiles of eight biomarkers. (b) Arg1, ST2, Thy1, KLRG1, IL-17RB, CCR9, and <t>CD69</t> protein contents, as evidenced by Western blot analysis. (c) S1P, S1P2, S1P3, S1P4, and S1P5 transcript expressions, as evidenced by qRT-PCR. (d) Lung ILC2s mRNA expression in murine COPD model treated with butyrate. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.01 (relative to control mice).
    Rabbit Anti Cd69 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti cd69 polyclonal antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    rabbit anti cd69 polyclonal antibody - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    94
    Bioss polyclonal rabbit anti murine cd69
    Assessing mCD69 expression in primary mouse T cells using flow cytometry and [89Zr]-DFO-H1.2F3 uptake. A, Scheme of <t>CD69</t> antibody binding: H1.2F3 monoclonal anti-CD69 binds to mCD69 on the surface of activated primary mouse T cells and other immune cells. B, Scheme of CD69 imaging: CD69 can be used as a biomarker to distinguish immunologically active tumors of mice that respond to checkpoint blockade (CBP) therapy (responders) from the tumors of mice that do not respond to therapy (nonresponders). C, Ex vivo flow cytometry analysis of CD69 expression for primary mouse T cells treated with PMA/ionomycin or untreated primary mouse T cells. D, Ex vivo [89Zr]-DFO-H1.2F3 uptake for primary mouse T cells treated with 50 ng/mL PMA and 1 μg/mL ionomycin, untreated primary mouse T cells, and CT26 cells. Uptake was measured on γ-counter and normalized to percent injected dose per million cells (% ID/106 cells). Error bars, SD.
    Polyclonal Rabbit Anti Murine Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit anti murine cd69/product/Bioss
    Average 94 stars, based on 1 article reviews
    polyclonal rabbit anti murine cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    86
    Danaher Inc rabbit polyclonal anti cd69 antibody
    Assessing mCD69 expression in primary mouse T cells using flow cytometry and [89Zr]-DFO-H1.2F3 uptake. A, Scheme of <t>CD69</t> antibody binding: H1.2F3 monoclonal anti-CD69 binds to mCD69 on the surface of activated primary mouse T cells and other immune cells. B, Scheme of CD69 imaging: CD69 can be used as a biomarker to distinguish immunologically active tumors of mice that respond to checkpoint blockade (CBP) therapy (responders) from the tumors of mice that do not respond to therapy (nonresponders). C, Ex vivo flow cytometry analysis of CD69 expression for primary mouse T cells treated with PMA/ionomycin or untreated primary mouse T cells. D, Ex vivo [89Zr]-DFO-H1.2F3 uptake for primary mouse T cells treated with 50 ng/mL PMA and 1 μg/mL ionomycin, untreated primary mouse T cells, and CT26 cells. Uptake was measured on γ-counter and normalized to percent injected dose per million cells (% ID/106 cells). Error bars, SD.
    Rabbit Polyclonal Anti Cd69 Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti cd69 antibody/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal anti cd69 antibody - by Bioz Stars, 2026-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.

    Journal: British Journal of Cancer

    Article Title: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus

    doi: 10.1038/s41416-024-02583-0

    Figure Lengend Snippet: a Kaplan–Meier curves for overall survival and disease-free survival for high-CD103 and low-CD103 pancreatic cancers from the TCGA database ( n = 187). b Kaplan–Meier curves for overall survival and disease-free survival for high-CD8 and low-CD8 pancreatic cancers ( n = 187). c Representative figures of immunofluorescent staining for CD8 (green), CD103 (red), DAPI (blue), and merge, for which the surgical specimen of patient 1 was used. Note that colocalization (yellow) of CD8 and CD103 means TRMs. Scale bar, 100 µm. d Clinicopathological characteristics of 12 patients with borderline resectable pancreatic ductal adenocarcinoma who underwent surgical resection are shown. G-N, G-U, P-N, and P-U mean good prognosis and NAC, good prognosis and upfront surgery, poor prognosis and NAC, and poor prognosis and upfront surgery, respectively. The cutoff period for a good or poor prognosis was defined as 24-month OS. e Twelve surgical specimens were subjected to immunohistochemical staining for CD8, CD103, and CD69. Representative images of each group (G-N, G-U, P-N, and P-U) are shown in ( e ). Scale bar, 200 µm. f , g The number of CD8+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( f ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( g ). h , i The number of CD103+ TILs assessed in six different, randomly selected fields is compared among 4 groups ( n = 3) ( h ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( i ). j , k The number of CD69+ TILs assessed in six different, randomly selected fields is compared among four groups ( n = 3) ( j ), and between poor and good prognosis groups and between upfront and NAC groups ( n = 6) ( k ). * P < 0.05, ** P < 0.005, *** P < 0.001. RFS relapse-free survival, OS overall survival, BR borderline resectable, PD pancreatoduodenectomy, GN gemcitabine + nab-paclitaxel, PR partial response, SD stable disease, NAC neoadjuvant chemotherapy.

    Article Snippet: After blocking endogenous peroxidase by 3% hydrogen peroxide and antigen retrieval by 14 min of microwave heating in EDTA buffer (pH 7.4), the samples were incubated with primary antibodies against CD8 (1:400, ab199016, Abcam, Cambridge, UK), CD103 (1:200, ab129202, Abcam), and CD69 (1:200, bs-2499R, Bioss, Woburn, MA, USA) overnight at 4 °C, and then incubated with peroxidase-linked secondary antibody for 30 min at room temperature.

    Techniques: Staining, Immunohistochemical staining

    SCFAs alleviate inflammatory cell activities in gut ILC2 cells. (a) t-SNE feature plots revealing profiles of eight biomarkers. (b) Arg1, ST2, Thy1, KLRG1, IL-17RB, CCR9, and CD69 protein contents, as evidenced by Western blot analysis. (c) S1P, S1P2, S1P3, S1P4, and S1P5 transcript expressions, as evidenced by qRT-PCR. (d) Lung ILC2s mRNA expression in murine COPD model treated with butyrate. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.01 (relative to control mice).

    Journal: Mediators of Inflammation

    Article Title: Dietary Fiber-Derived Microbial Butyrate Suppresses ILC2-Dependent Airway Inflammation in COPD

    doi: 10.1155/2024/6263447

    Figure Lengend Snippet: SCFAs alleviate inflammatory cell activities in gut ILC2 cells. (a) t-SNE feature plots revealing profiles of eight biomarkers. (b) Arg1, ST2, Thy1, KLRG1, IL-17RB, CCR9, and CD69 protein contents, as evidenced by Western blot analysis. (c) S1P, S1P2, S1P3, S1P4, and S1P5 transcript expressions, as evidenced by qRT-PCR. (d) Lung ILC2s mRNA expression in murine COPD model treated with butyrate. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.01 (relative to control mice).

    Article Snippet: The membrane was blocked with 5% nonfat milk at room temperature for 2 hr and further incubated overnight with rabbit anti-arginase1 (anti-Arg1) (Sangon Biotech, Shanghai, China), Thy.1 monoclonal antibody (Proteintech Group, Inc, Wuhan, China), ST2 monoclonal antibody (Proteintech Group, Inc., Wuhan, China), rabbit antikiller cell lectin-like receptor G1 (KLRG1) (Abcam, Cambridge, MA, USA), rabbit anti-IL17RB antibody (bioss, Bejing, China), anti-CCR9 antibody (BosterBio, USA), rabbit anti-CD69 polyclonal antibody (absin, Shanghai, China), NFIL3 polyclonal antibody (Proteintech Group, Inc., Wuhan, China), rabbit anti-GATA3 polyclonal antibody (absin, Shanghai, China), histone-H3 polyclonal antibody (Proteintech Group, Inc., Wuhan, China), rabbit anti-acetyl-histone H3 monoclonal antibody (absin, Shanghai, China), or β -actin polyclonal antibody (Proteintech Group, Inc., Wuhan, China) at 4°C.

    Techniques: Western Blot, Quantitative RT-PCR, Expressing, Control

    Assessing mCD69 expression in primary mouse T cells using flow cytometry and [89Zr]-DFO-H1.2F3 uptake. A, Scheme of CD69 antibody binding: H1.2F3 monoclonal anti-CD69 binds to mCD69 on the surface of activated primary mouse T cells and other immune cells. B, Scheme of CD69 imaging: CD69 can be used as a biomarker to distinguish immunologically active tumors of mice that respond to checkpoint blockade (CBP) therapy (responders) from the tumors of mice that do not respond to therapy (nonresponders). C, Ex vivo flow cytometry analysis of CD69 expression for primary mouse T cells treated with PMA/ionomycin or untreated primary mouse T cells. D, Ex vivo [89Zr]-DFO-H1.2F3 uptake for primary mouse T cells treated with 50 ng/mL PMA and 1 μg/mL ionomycin, untreated primary mouse T cells, and CT26 cells. Uptake was measured on γ-counter and normalized to percent injected dose per million cells (% ID/106 cells). Error bars, SD.

    Journal: Cancer immunology research

    Article Title: Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation

    doi: 10.1158/2326-6066.CIR-21-0874

    Figure Lengend Snippet: Assessing mCD69 expression in primary mouse T cells using flow cytometry and [89Zr]-DFO-H1.2F3 uptake. A, Scheme of CD69 antibody binding: H1.2F3 monoclonal anti-CD69 binds to mCD69 on the surface of activated primary mouse T cells and other immune cells. B, Scheme of CD69 imaging: CD69 can be used as a biomarker to distinguish immunologically active tumors of mice that respond to checkpoint blockade (CBP) therapy (responders) from the tumors of mice that do not respond to therapy (nonresponders). C, Ex vivo flow cytometry analysis of CD69 expression for primary mouse T cells treated with PMA/ionomycin or untreated primary mouse T cells. D, Ex vivo [89Zr]-DFO-H1.2F3 uptake for primary mouse T cells treated with 50 ng/mL PMA and 1 μg/mL ionomycin, untreated primary mouse T cells, and CT26 cells. Uptake was measured on γ-counter and normalized to percent injected dose per million cells (% ID/106 cells). Error bars, SD.

    Article Snippet: To probe for CD69, a polyclonal rabbit anti-murine CD69 was used (1:50; 1 mg/mL; Bioss, catalog no. bs-2499R) followed by a goat anti-rabbit IgG amplifier Ab and an horseradish peroxidase (HRP)-conjugated horse anti-goat Ab (ImmPRESS Excel Amplified Polymer Staining Kit, Vector Laboratories, catalog no. MP-7451-15).

    Techniques: Expressing, Flow Cytometry, Binding Assay, Imaging, Biomarker Assay, Ex Vivo, Injection

    Validating CD69 expression in a CT26 syngeneic tumor immunotherapy model using ex vivo autoradiography and IHC. A, Representative autoradiography images of whole tumor sections from responders, nonresponders, and untreated control groups. B, 20x magnified histological and IHC images of CD69 expression (NovaRED) on tumors sections from responders, nonresponders, and untreated control groups. Scale bar, 100 μmol/L.

    Journal: Cancer immunology research

    Article Title: Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation

    doi: 10.1158/2326-6066.CIR-21-0874

    Figure Lengend Snippet: Validating CD69 expression in a CT26 syngeneic tumor immunotherapy model using ex vivo autoradiography and IHC. A, Representative autoradiography images of whole tumor sections from responders, nonresponders, and untreated control groups. B, 20x magnified histological and IHC images of CD69 expression (NovaRED) on tumors sections from responders, nonresponders, and untreated control groups. Scale bar, 100 μmol/L.

    Article Snippet: To probe for CD69, a polyclonal rabbit anti-murine CD69 was used (1:50; 1 mg/mL; Bioss, catalog no. bs-2499R) followed by a goat anti-rabbit IgG amplifier Ab and an horseradish peroxidase (HRP)-conjugated horse anti-goat Ab (ImmPRESS Excel Amplified Polymer Staining Kit, Vector Laboratories, catalog no. MP-7451-15).

    Techniques: Expressing, Ex Vivo, Autoradiography

    Correlating CD69 IHC with immune lineage markers. A, Representative tumor sections from responder and nonresponder mice. Tumor sections were assayed for the CD69 activation marker using NovaRED, and for CD4, CD8, and CD45 lineage markers using DAB staining. Scale bar, 250 μmol/L. B to E, Quantification of the number of positively stained cells per high power field (HPF) for responder and nonresponder tumor sections, at 10x magnification. Scale bars, 250 μm. Two-tailed unpaired t test was used to compare groups., P < 0.05; **, P < 0.01; ***, P < 0.001;, P < 0.0001. n = 3 tumors per group with three measurements per HPF per tumor.

    Journal: Cancer immunology research

    Article Title: Using CD69 PET Imaging to Monitor Immunotherapy-Induced Immune Activation

    doi: 10.1158/2326-6066.CIR-21-0874

    Figure Lengend Snippet: Correlating CD69 IHC with immune lineage markers. A, Representative tumor sections from responder and nonresponder mice. Tumor sections were assayed for the CD69 activation marker using NovaRED, and for CD4, CD8, and CD45 lineage markers using DAB staining. Scale bar, 250 μmol/L. B to E, Quantification of the number of positively stained cells per high power field (HPF) for responder and nonresponder tumor sections, at 10x magnification. Scale bars, 250 μm. Two-tailed unpaired t test was used to compare groups., P < 0.05; **, P < 0.01; ***, P < 0.001;, P < 0.0001. n = 3 tumors per group with three measurements per HPF per tumor.

    Article Snippet: To probe for CD69, a polyclonal rabbit anti-murine CD69 was used (1:50; 1 mg/mL; Bioss, catalog no. bs-2499R) followed by a goat anti-rabbit IgG amplifier Ab and an horseradish peroxidase (HRP)-conjugated horse anti-goat Ab (ImmPRESS Excel Amplified Polymer Staining Kit, Vector Laboratories, catalog no. MP-7451-15).

    Techniques: Activation Assay, Marker, Staining, Two Tailed Test